Discontinued operations (Tables) - Discontinued operations

6 Months Ended

Jun. 30, 2020

Statement [line items]

Consolidated income statement, discontinued operations

(USD millions)	Q2 2019 1	H1 2019
Net sales to third parties from discontinued operations		1 777
Sales to continuing segments		32
Net sales from discontinued operations		1 809
Cost of goods sold		– 860
Gross profit from discontinued operations		949
Selling, general and administration		– 638
Research and development		– 142
Other income		15
Other expense		– 113
Operating income from discontinued operations		71
as % of net sales		4.0%
Interest expense		– 10
Other financial income and expense		– 3
Income before taxes from discontinued operations		58
Taxes		– 159
Net loss from discontinued operations before gain on distribution of Alcon Inc. to Novartis AG shareholders		– 101
Gain on distribution of Alcon Inc. to Novartis AG shareholders  2	4 691	4 691
Net income from discontinued operations  2	4 691	4 590
1  As the Alcon spin-off was completed on April 9, 2019, the Q2 2019 results of operations from the Alcon business were not material.
2  See Note 3 for further details on the non-taxable non-cash gain on distribution of Alcon Inc. to Novartis AG shareholders recognized on April 8, 2019, date of Distribution.

Cash flows used in investing activities

(USD millions)	Q2 2020	Q2 2019	H1 2020	H1 2019
Payments attributable to the spin-off of the Alcon business	– 3	– 14	– 17	– 14
Divested cash and cash equivalents		– 628		– 628
Cash flows attributable to the spin-off of the Alcon business	– 3	– 642	– 17	– 642
Other cash flows used in investing activities, net	– 88	– 40	– 88	– 463
Net cash flows used in investing activities from discontinued operations	– 91	– 682	– 105	– 1 105